Research graph
References from Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence. Local targets link to admitted publications; unresolved targets remain external evidence.
Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey
10.1016/s2213-8587(22)00219-4 · 2022 · External reference
Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency
10.1038/s41574-024-00985-x · 2024 · External reference
Machine learning for detection of safety signals from spontaneous reporting system data: example of nivolumab and docetaxel
10.3389/fphar.2020.602365 · 2021 · External reference
Suspected adverse drug reactions related to breast cancer chemotherapy: disproportionality analysis of the Brazilian spontaneous reporting system
10.3389/fphar.2019.00498 · 2019 · External reference
Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol
10.1002/pds.1742 · 2009 · External reference
Adverse drug reaction risk measures: a comparison of estimates from drug surveillance and randomised trials
10.1007/s40290-019-00287-y · 2019 · External reference
Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system
10.1016/j.intimp.2021.107498 · 2021 · External reference
PD-1/PD-L1 inhibitors associated hypophysitis: an analysis from the FAERS database and case reports
10.5582/ddt.2023.01092 · 2024 · External reference
Diabetes insipidus
10.1038/s41572-019-0103-2 · 2019 · External reference
Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database
10.1136/bmjophth-2024-001764 · 2024 · External reference
Factors associated with underreporting of adverse drug reactions by patients: a systematic review
10.1007/s11096-023-01592-y · 2023 · External reference
Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features
10.1007/s00432-023-04659-5 · 2023 · External reference
Case-non-case studies: principle, methods, bias and interpretation
10.1016/j.therap.2019.01.006 · 2019 · External reference
Central and nephrogenic diabetes insipidus: updates on diagnosis and management
10.3389/fendo.2024.1479764 · 2025 · External reference
Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update
10.1007/s40264-023-01302-7 · 2023 · External reference
Lithium nephrotoxicity revisited
10.1038/nrneph.2009.43 · 2009 · External reference
More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis
10.1002/pds.5265 · 2021 · External reference
Under-reporting of adverse drug reactions: a systematic review
10.2165/00002018-200629050-00003 · 2006 · External reference
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class
10.1371/journal.pone.0042866 · 2012 · External reference
The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010
10.1007/s40264-014-0150-2 · External reference
Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS)
10.1007/s40264-014-0225-0 · External reference
Combining a pharmacological network model with a Bayesian signal detection algorithm to improve the detection of adverse drug events
10.3389/fphar.2021.773135 · 2022 · External reference
Lithium-induced nephrogenic diabetes insipidus with efficacy of desmopressin in combination with thiazide diuretics and non-steroidal anti-inflammatory drugs: a case report with a review of the literature
10.2169/internalmedicine.2437-23 · 2024 · External reference
A standardized dataset of a spontaneous adverse event reporting system
10.3390/healthcare10030420 · 2022 · External reference
Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus
10.1038/ki.2009.91 · 2009 · External reference
Diabetes insipidus related to sedation in the intensive care unit: a review of the literature
10.1016/j.jcrc.2022.154233 · 2023 · External reference
Diabetes insipidus induced by oral olanzapine at therapeutic dose
10.1177/02537176221109962 · 2023 · External reference
International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)
10.1038/s41581-024-00897-z · 2025 · External reference
Safety assessment of obinutuzumab: real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025
10.1371/journal.pone.0334317 · 2025 · External reference
Real-world pharmacovigilance study of drug-induced diabetes insipidus from the FAERS database
10.1530/ec-25-0734 · 2026 · External reference
FDA Adverse Event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS
10.1002/cpt.3701 · 2025 · External reference
Data mining of the public version of the FDA Adverse Event Reporting System
10.7150/ijms.6048 · 2013 · External reference
Diagnosis and management of central diabetes insipidus in adults
10.1210/clinem/dgac381 · 2022 · External reference
Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature
10.1213/ane.0000000000005344 · 2022 · External reference
Cancer-related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: a real-world analysis using the FDA adverse event reporting system
10.1371/journal.pone.0329385 · 2025 · External reference
A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors
10.1038/s41698-025-01123-0 · 2025 · External reference
Clinical characteristics of central diabetes insipidus: a retrospective analysis of 230 cases
10.3760/cma.j.issn.0578-1426.2018.03.010 · 2018 · External reference
